By - Reuters
March 20 (Reuters) - Moonlake Immunotherapeutics :
* REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
* TOP-LINE RESULTS FOR A PHASE 2 TRIAL OF SONELOKIMAB IN ACTIVE PSA ANTICIPATED ON SCHEDULE AT THE END OF THE YEAR
* QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO CONTROLLING INTERESTS SHAREHOLDERS $ 0.31
* Q4 EARNINGS PER SHARE VIEW $-0.33 -- REFINITIV IBES DATA
* TOP-LINE RESULTS FOR GLOBAL PHASE 2 TRIAL OF SONELOKIMAB IN HS EXPECTED AROUND END OF JUNE AND FINAL READ-OUT BY Q4 Source text for Eikon: Further company coverage: